Search Results
Jul 15, 2026, 07:45 ET Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Keynote-522, standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates are only 63%, with rates generally lower in the larger-sized T2 to T4 tumors. The toxicity of the Keynote-522
More news about: Intensity Therapeutics Inc.
Jul 15, 2026, 03:00 ET Power Metallic reports New Lion drill intercepts of 36.42 Meters of 2.83% CuEqRec1 in Hole 26-116 including 6.00 Meters of 12.38% CuEqRec1 and Announces AGSM Meeting Results
individual assays of up to 0.49 g/t Pt and 0.62 g/t Pd, as well as anomalous Cu and Au, defining the mineralized structure's location. Two holes also tested near surface between Lion and Tiger, again intersecting the mineralized structure with weak Cu, Pd results.
More news about: Power Metallic Mines Inc.
Jul 14, 2026, 21:09 ET GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
world."CX-5461 is currently involved in studies sponsored by the NCI and Senhwa expects to initiate a clinical study combining the drug with BeOne Medicines' PD-1 antibody, tislelizumab. CX-4945 is being investigated across several oncology indications, including cholangiocarcinoma, CNS tumors and pediatric cancers.
More news about: Senhwa Biosciences, Inc
Jul 14, 2026, 20:00 ET 全球首個ADC+IO對比免疫聯合化療一線治療PD-L1陰性非鱗狀NSCLC III期研究達到主要終點，蘆康沙妥珠單抗聯合帕博利珠單抗有望重塑治療格局
6990.HK)宣佈，公司靶向人滋養細胞表面抗原2(TROP2)的抗體偶聯藥物(ADC)蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)聯合帕博利珠單抗(可瑞達®[1]，默沙東[2]的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體-1(PD-L1)陰性的局部晚期或轉移性非鱗狀非小細胞肺癌(NSCLC)的III期臨床研究(OptiTROP-Lung06)，在預設的期中分析中，經獨立數據監查委員會(IDMC)確認達到無進展生存期(PFS)主要終點。這是全球首個ADC聯合免疫檢查點抑制劑在一線治療驅動基因陰性、PD-L1陰性非鱗狀NSCLC上達到主要終點的III期臨床研究。
More news about: 科倫博泰
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
to unlock the therapeutic potential of the PD-1 mAb in patients with PD-L1-negative or limited immune responses, breaking this therapeutic bottleneck.Following the meeting of the primary endpoint in the Phase III OptiTROP-Lung05 study for first-line PD-L1-positive NSCLC, the positive results were
More news about: Kelun-Biotech
Jul 14, 2026, 10:00 ET ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease
today announced the peer-reviewed publication in Nature Medicine of Phase 1b data from IBC-01-01 evaluating IBC-Ab002, its investigational anti-PD-L1 antibody, in patients with early Alzheimer's disease. The publication coincides with a late-breaking presentation at the Alzheimer's Association International
More news about: ImmunoBrain Checkpoint Inc.
Jul 14, 2026, 06:52 ET nubia Neo 5 GT Special Edition redefine el gaming con su sistema de refrigeración líquida, único en su segmento
una tasa de fotogramas alta y estable. Este dispositivo incorpora una batería de doble celda de 6.210 mAh, compatible con carga rápida de 80 W (45 W PD para el mercado europeo) y carga bypass. También admite el "Modo Extreme 5 %", que proporciona hasta 30 minutos adicionales de juego con solo el 5 %
More news about: ZTE Corporation
Jul 14, 2026, 04:18 ET Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
48%. Although the addition of PD-1 inhibitors to FLOT has become the new standard of care, the pathologic complete response (pCR) rate remains limited at approximately 19%, and nearly one-third of patients experience disease recurrence or death within two years. Dual PD-1/CTLA-4 inhibition has shown
More news about: Akeso, Inc.
Jul 13, 2026, 12:00 ET Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
plan remain essential to deal execution.Deals often stall due to weak biological rationale, unclear patient or biomarker strategies, poor PK/PD or therapeutic windows, and inadequate global development planning.The second panel was moderated by Kenneth C. Chen, Senior Director of
More news about: ACROBiosystems
Jul 13, 2026, 10:03 ET nubia Neo 5 GT Special Edition debütiert mit erstem und einzigem aktivem Dual-Kühlsystem mit Flüssigkeits- und Luftkühlung seiner Klasse
Gerät darauf ausgelegt, hohe und stabile Bildraten zu liefern. Das Gerät verfügt über einen 6.210-mAh-Zweizellen-Akku, der durch 80-W-Schnellladung (45 W PD für den EU-Markt) und Bypass-Ladung unterstützt wird. Außerdem unterstützt es den 5 %-Extremmodus, mit dem sich die Spielzeit um bis zu 30 Minuten verlängern
More news about: ZTE Corporation
Jul 13, 2026, 10:00 ET Pete Hall releases new book to help educators reach every student
Global PD Teams and
More news about: Solution Tree
Jul 13, 2026, 09:16 ET HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence
first.3. Bridging endpoint designConnects pharmacodynamic endpoints, mechanism endpoints, translational biomarkers, PK exposure, PK/PD correlation and basic safety observations.HKeyBio integrates disease models, NHP research and translational reportingDeliverables
More news about: HKeyBio
Jul 13, 2026, 08:01 ET Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
feasibility and dosing of the Hemopurifier® in patients with advanced solid tumors whose cancers have progressed despite treatment with anti-PD-1 immunotherapies.The second cohort continued to show directional changes in several biomarkers that researchers believe are associated with tumor
More news about: Aethlon Medical, Inc.
Jul 13, 2026, 06:59 ET Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a
More news about: Q32 Bio
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist
More news about: Leads Biolabs
Jul 13, 2026, 00:08 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
session highlighted findings from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience data.Results showed that once-weekly 500 mg SC-AI achieved drug exposure
More news about: BioArctic
Jul 13, 2026, 00:02 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
session highlighted findings from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience data.Results showed that once-weekly 500 mg SC-AI achieved drug exposure
More news about: BioArctic
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Jul 12, 2026, 11:15 ET LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
FindingsThis session presented data from the lecanemab SC-AI development program in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience findings. Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar
More news about: Eisai Inc.
Jul 11, 2026, 08:05 ET Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
et al. Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2026. July 11-15,
More news about: Novo Nordisk
Jul 11, 2026, 08:05 ET Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
et al. Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2026. July 11-15,
More news about: Novo Nordisk
Jul 10, 2026, 06:48 ET De nubia Neo 5 GT Special Edition wordt gelanceerd met het eerste en enige dubbele actieve koelsysteem op basis van vloeistof en lucht in zijn klasse
stabiele framerates te leveren. Dit apparaat is uitgerust met een 6.210 mAh-batterij met twee cellen, die ondersteuning biedt voor snelladen met 80 W (45 W PD voor de EU-markt) en bypass-opladen. Het ondersteunt ook de 5% Extreme-modus, waardoor men tot 30 minuten langer kan gamen.Een onderdompelende
More news about: ZTE Corporation
Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist
More news about: Nanjing Leads Biolabs Co., Ltd.
Jul 10, 2026, 02:39 ET nubia Neo 5 GT Special Edition 출시, 동급 최초 유일 액체•공기 이중 능동 냉각 시스템 탑재
Engine 최적화로 구성된 Cold-Core Trinity를 기반으로 높은 프레임 속도를 안정적으로 유지하도록 설계됐다. 이 제품에는 6210mAh 듀얼 셀 배터리가 탑재됐으며, 80W 고속 충전과 Bypass Charging을 지원한다. 유럽연합(EU) 시장에서는 45W PD 고속 충전을 지원한다. 또한 5% Extreme Mode가 지원돼 추가로 최대 30분 추가 게임이 가능하다.AI Copilot Demi로 강화된 몰입형 게이밍 경험nubia Neo 5 GT Special Edition은 144Hz
More news about: ZTE Corporation
Jul 09, 2026, 11:32 ET O nubia Neo 5 GT Special Edition estreia com o primeiro e único sistema de resfriamento híbrido, a líquido e a ar, da sua categoria
para oferecer taxas de quadros altas e estáveis. Ele possui uma bateria de duas células de 6.210 mAh, com suporte para carregamento rápido de 80 W (45 W PD para o mercado da UE) e carregamento bypass. Ele também suporta o modo extremo de 5%, oferecendo até 30 minutos extras de jogo.A experiência
More news about: ZTE Corporation